Evidence map›Paper›PMID 35110256›Full record

ArticleTurkish thoracic journal2021

Association Between Cystic Fibrosis Severity Markers and CFTR Genotypes in Turkish Children.

Abdurrahman Erdem Başaran, Ayşen Başaran, Dilara Fatma Kocacik Uygun, Elanur Yılmaz, Asef Moballegh, Latife Öz, Özgül Alper, Ayşen Bingöl

Open access · greenAbstract read
In one paragraph

Article in Turkish thoracic journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. The globalization of cystic fibrosis care.Current opinion in pediatrics · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Abdurrahman Erdem BaşaranDivision of Pediatric Pulmonology, Akdeniz University School of Medicine, Antalya, Turkey.
Ayşen BaşaranDepartment of Pediatrics, Akdeniz University School of Medicine, Antalya, Turkey.
Dilara Fatma Kocacik UygunDepartment of Pediatrics, Division of Allergy Immunology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
Elanur YılmazDepartment of Medical Biology and Genetics, Akdeniz University, Faculty of Medicine, Antalya, Turkey.
Asef MoballeghDepartment of Medical Biology and Genetics, Akdeniz University, Faculty of Medicine, Antalya, Turkey.
Latife ÖzDepartment of Pediatrics, Akdeniz University, Faculty of Medicine, Antalya, Turkey.
Özgül AlperDepartment of Medical Biology and Genetics, Akdeniz University, Faculty of Medicine, Antalya, Turkey.
Ayşen BingölDivision of Pediatric Pulmonology, Akdeniz University School of Medicine, Antalya, Turkey.
Akdeniz University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare class I/II cystic fibrosis transmembrane conductance regulator (CFTR) mutations to class III-V mutations with regards to cystic fibrosis disease severity markers in children. MATERIAL AND

methodsThis study was designed as a cross-sectional study in Antalya province, located on the south coast of Turkey. The study included 38 cystic fibrosis patients aged between 0.6 and 18 years. The CFTR genotype of the patients was categorized into 2 groups based on the presence or absence of class I or class II mutations in any of the alleles. Group I comprised 8 homozygous, 8 with unknown alleles, and 8 compound heterozygous patients, and group II comprised 11 homozygous and 3 compound heterozygous patients. The groups were analyzed in respect of cystic fibrosis disease severity markers, such as spirometry, ShwachmanKulczycki score, body mass index (BMI), sweat chloride concentration, chronic Pseudomonas aeruginosa infection, annual exacerbation frequency, and severe exacerbations requiring hospitalization during the previous year.

resultsIn the comparison of group I and group II patients, a significant difference was observed in pancreas insufficiency (83.3% vs. 35.7%; P = .005), chronic P. aeruginosa infection (58.3% vs. 7.1%; P = .002), cough severity score (1.7 ± 1.1 vs. 0.9 ± 1.5; P = .029), number of severe exacerbations requiring hospitalization during the previous year (0.9 ± 1 vs. 0.3 ± 0.8; P = .03), and sweat chloride levels (76.7 ± 15.2 vs. 61 ± 22.3; P = .02). All these values were higher in group I patients. The mean BMI values (15.8 ± 2.2 vs. 17.6 ± 2.8; P = .03) were lower in group I patients.

conclusionThere seems to be a difference between class I/II CFTR mutations and class III-V mutations on the severity of the disease in cystic fibrosis patients.

Identifiers

PMID35110256
PMCPMC8975339
OpenAlexW3216281919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.